Novartis Ventures et al. in £8.65m round for ITS
Novartis Ventures, Sweden’s HealthCap, France’s Truffle Capital and London Technology Fund, have participated in a £8.65m funding round for British biotech company Immune Targeting Systems (ITS).
More on Healthcare
Women in PE: Triton’s Meier-Kirner on deploying in times of crisis and resisting herd mentality
Pan-European sponsor aims to back undervalued businesses and those with structural tailwinds using learnings from past crises
Armonia exits Italy’s BioDue in SBO to Riverside Europe
Sale of food supplement and medical devices group marks second exit from Armònia Italy Fund
CapMan to return to market for new growth fund in 2024
With EUR 100m-150m target, fundraising will launch after CapMan Growth II's full deployment
The Bolt-Ons Digest – 11 November 2022
Unquote’s selection of the latest add-ons including Hg and ICG's Iris, Inflexion's THE, Bain's House of HR and more
Latest News
Carlyle hires advisers to explore DEPT sale in 2023
Morgan Stanley and Jefferies will guide GP on potential exit of Dutch digital agency
Livingbridge appoints new head of services
Investment director Matt Jacobs to lead mid-market GP’s sector team from London office
Adelis sells Mobilhouse to consortium led by LEGO’s family office
Kirk Kapital takes 50% in Danish modular building group alongside individual investors
Earlybird opens London office to step up UK and Ireland deployment
Germany-based VC firm plans to invest 15-20% of its latest EUR 350m Digital West fund in the region